The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
FTC targets 300 Big Pharma 'junk patents,' sends warning letters to top drugmakers The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book ...
The decision comes after the FTC's warnings to drugmakers over the misuse of Orange Book patent listings to wrongly extend ...
The cost of drugs in the U.S. continues to skyrocket. The average drug price increase from 2022 to 2023 was 15%, according to ...
Over the last eight months, the US Federal Trade Commission (FTC) has focused on what it characterizes as “improper” Orange Book listings and the impacts of such listings on generic entry.
In a significant ruling, the United States District Court for the District of New Jersey has ordered that Teva’s inhaler ...
Democrats have hit on a new tactic in their long battle with drug companies: challenge patents that they say are deliberate attempts to game the system and box out low-cost, generic competitors.
Drugmaker Amneal Pharmaceuticals with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court ...
The cost of drugs in the U.S. continues to skyrocket. The average drug price increase from 2022 to 2023 was 15%, according to ...